Drug Markets/Ustekinumab

Ustekinumab

2 NDCs across 1 manufacturer|0 Generic,2 Brand

Ustekinumab is used to treat psoriatic arthritis, ulcerative colitis, crohn disease and psoriasis, per the National Library of Medicine's MED-RT classification.

▸ More about this market

In 2024, Medicare Part D spent $3.4 billion on Ustekinumab across 133,000 claims for 25,000 beneficiaries.

Ustekinumab is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $29792.79 to $29874.45 per MLa 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

2

0G / 2B

Manufacturers

1

competing in market

Price Spread

$29792.79 – $29874.45

per ML

7d Activity

20 flat

avg -0.2% WoW · of 2 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing USTEKINUMAB

Drug Portfolio

2 NDCs total, 2 shown

Drug Price 7d Change
STELARA 45 MG/0.5 ML SYRINGE
$29874.4480
per ML
STELARA 90 MG/ML SYRINGE
$29792.7867
per ML
-0.17%

Frequently Asked Questions

What is Ustekinumab used to treat?

Ustekinumab is used to treat psoriatic arthritis, ulcerative colitis, crohn disease and psoriasis, per the National Library of Medicine's MED-RT classification.

How much does Medicare spend on Ustekinumab?

In 2024, Medicare Part D spent $3.4 billion on Ustekinumab across 133,000 claims for 25,000 beneficiaries.

How many Ustekinumab products are on the market?

The Ustekinumab drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.

What is the price range for Ustekinumab?

NADAC reference prices for Ustekinumab range from $29792.7867 to $29874.4480 per ML — a 0% difference between cheapest and most expensive.

Which manufacturers make Ustekinumab?

1 manufacturer lists Ustekinumab in NADAC. Ranked by number of NDCs, the largest are Janssen Biotech, Inc. (2).

How has the price of Ustekinumab changed recently?

Over the past 7 days, 0 Ustekinumab NDCs rose and 2 fell, with a market-wide average change of -0.2%.